The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.

Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.